217 related articles for article (PubMed ID: 25589097)
1. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.
Sabatini S; Manfroni G; Barreca ML; Bauer SM; Gargaro M; Cannalire R; Astolfi A; Brea J; Vacca C; Pirro M; Massari S; Tabarrini O; Loza MI; Fallarino F; Laufer SA; Cecchetti V
Chem Biol Drug Des; 2015 Oct; 86(4):531-45. PubMed ID: 25589097
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.
Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
Bioorg Med Chem Lett; 2010 May; 20(9):2765-9. PubMed ID: 20378346
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
[TBL] [Abstract][Full Text] [Related]
4. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
Somakala K; Tariq S; Amir M
Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors.
Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ
Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577
[TBL] [Abstract][Full Text] [Related]
7. Differential roles of JNK, ERK1/2, and p38 mitogen-activated protein kinases on endothelial cell tissue repair functions in response to tumor necrosis factor-α.
Kanaji N; Nelson A; Wang X; Sato T; Nakanishi M; Gunji Y; Basma H; Michalski J; Farid M; Rennard SI; Liu X
J Vasc Res; 2013; 50(2):145-56. PubMed ID: 23258237
[TBL] [Abstract][Full Text] [Related]
8. Discovery of naphthyl-N-acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity.
Freitas RHCN; Cordeiro NM; Carvalho PR; Alves MA; Guedes IA; Valerio TS; Dardenne LE; Lima LM; Barreiro EJ; Fernandes PD; Fraga CAM
Chem Biol Drug Des; 2018 Feb; 91(2):391-397. PubMed ID: 28815968
[TBL] [Abstract][Full Text] [Related]
9. TAK1 inhibition in the DFG-out conformation.
Kilty I; Green MP; Bell AS; Brown DG; Dodd PG; Hewson C; Hughes SJ; Phillips C; Ryckmans T; Smith RT; van Hoorn WP; Cohen P; Jones LH
Chem Biol Drug Des; 2013 Nov; 82(5):500-5. PubMed ID: 23745990
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, p38α MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines.
Tariq S; Alam O; Amir M
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700304. PubMed ID: 29611883
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies for inhibition of the p38 MAPK pathway.
Zhang J; Shen B; Lin A
Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683
[TBL] [Abstract][Full Text] [Related]
13. Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening.
Gangwal RP; Das NR; Thanki K; Damre MV; Dhoke GV; Sharma SS; Jain S; Sangamwar AT
J Mol Graph Model; 2014 Apr; 49():18-24. PubMed ID: 24473068
[TBL] [Abstract][Full Text] [Related]
14. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA
ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280
[TBL] [Abstract][Full Text] [Related]
15. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
Yego EC; Dillman JF
Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068
[TBL] [Abstract][Full Text] [Related]
17. Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.
Leo V; Stefanachi A; Nacci C; Leonetti F; de Candia M; Carotti A; Altomare CD; Montagnani M; Cellamare S
J Pharm Pharmacol; 2015 Oct; 67(10):1380-92. PubMed ID: 26078032
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors.
Dorn A; Schattel V; Laufer S
Bioorg Med Chem Lett; 2010 May; 20(10):3074-7. PubMed ID: 20418099
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
Grund EM; Kagan D; Tran CA; Zeitvogel A; Starzinski-Powitz A; Nataraja S; Palmer SS
Mol Pharmacol; 2008 May; 73(5):1394-404. PubMed ID: 18252806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]